Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2019-08-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于第六届董事会第十九次会议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 19th meeting of the 6th Board of Directors of Anhui Anke Biotechnology (Group) Co., Ltd. It includes voting results on various corporate matters such as approval of the 2019 semi-annual report, related party transactions, stock incentive plans, stock repurchases, capital reduction, and accounting policy changes. The document is structured as a formal board meeting announcement with detailed voting outcomes and references to other announcements for further details. It does not contain the full semi-annual report or detailed financial statements itself but rather the board's decisions and approvals. The document length is under 5,000 characters and serves as a formal disclosure of board resolutions and voting results. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2019-08-27 Chinese
安徽天禾律师事务所关于公司第二期限制性股票激励计划首次授予的限制性股票第三次解锁、第二期限制性股票激励计划预留授予的限制性股票第二次解锁及回购注销部分限制性股票相关事项之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's second phase restricted stock incentive plan, specifically about the unlocking and repurchase cancellation of restricted stocks. It references detailed legal and regulatory frameworks such as the Securities Law, Company Law, and stock incentive management measures. The document includes approvals from the board, supervisory board, and shareholders, and discusses compliance with relevant regulations. It is not a financial report, earnings release, or management discussion, but a legal opinion related to stock incentive plan implementation and related corporate actions. This fits best under the category of Regulatory Filings (RNS), as it is a legal opinion and compliance document rather than a financial report or announcement of voting results or capital changes. The document length and content confirm it is not a brief announcement but a substantive legal opinion letter.
2019-08-27 Chinese
2019年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2019 年半年度报告摘要' which translates to '2019 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also discusses operational highlights, R&D progress, patent information, and management commentary on business performance. The document length is 9681 characters, which is substantial and contains actual financial statements and analysis, not just an announcement or summary. The presence of detailed financial tables and management discussion confirms it is a comprehensive interim report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-27 Chinese
国元证券股份有限公司关于公司向其参股公司提供财务资助暨关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Guoyuan Securities Co., Ltd. regarding financial assistance and related party transactions provided by Anhui Anke Biotechnology (Group) Co., Ltd. to its associate company. It includes detailed descriptions of the financial assistance, the recipient company, risk control measures, board opinions, independent directors' opinions, cumulative financial assistance amounts, and the sponsor's verification opinion. The document references regulatory rules and approval procedures but does not contain financial statements or quarterly/yearly financial results. It is a regulatory compliance and verification report related to a specific transaction rather than a financial report or earnings release. The document length is 4367 characters, which is relatively short but contains substantive content about a specific transaction and related opinions. This fits best under Regulatory Filings (RNS) as it is a compliance and verification document that does not fit other categories like Annual Report, Interim Report, or Capital/Financing Update. Therefore, the classification is RNS with high confidence.
2019-08-27 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the reasons for the change, the new accounting policies adopted, and the approvals from the board, supervisory committee, and independent directors. The document does not contain actual financial statements or detailed financial data but rather explains the policy change and its rationale. It is a regulatory announcement about accounting policy changes, not a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS). The document length is 2371 characters, which is relatively short and consistent with an announcement rather than a full report.
2019-08-27 Chinese
关于公司向参股公司提供财务资助暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the provision of financial assistance to an associate company, Boson Janke Cell Technology Co., Ltd., which constitutes a related party transaction. The document details the terms of the financial assistance, the background of the associate company, risk control measures, opinions from the board of directors, independent directors, and the sponsor institution, as well as cumulative financial assistance amounts. It is a formal disclosure about a related party transaction and financial support, not a financial report, earnings release, or management discussion. It does not contain financial statements or quarterly/annual results but is a regulatory announcement about a specific corporate action. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-08-27 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.